HUP0201582A2 - Use of il-8 receptor antagonist benzimidazoles and benzotriazoles - Google Patents

Use of il-8 receptor antagonist benzimidazoles and benzotriazoles

Info

Publication number
HUP0201582A2
HUP0201582A2 HU0201582A HUP0201582A HUP0201582A2 HU P0201582 A2 HUP0201582 A2 HU P0201582A2 HU 0201582 A HU0201582 A HU 0201582A HU P0201582 A HUP0201582 A HU P0201582A HU P0201582 A2 HUP0201582 A2 HU P0201582A2
Authority
HU
Hungary
Prior art keywords
optionally substituted
group
alkyl
substituted alkyl
heteroarylalkyl
Prior art date
Application number
HU0201582A
Other languages
Hungarian (hu)
Inventor
Gregory Martin Benson
Melvin Clarence Rutledge
Katherine L. Widdowson
Original Assignee
Smithkline Beecham Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp. filed Critical Smithkline Beecham Corp.
Publication of HUP0201582A2 publication Critical patent/HUP0201582A2/en
Publication of HUP0201582A3 publication Critical patent/HUP0201582A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány (I) általános képletű vegyületek (I) ábra következik -amelyek képletében R -NH-C(X2)-NH-(CR13R14)v-Z csoport; Z W, HET,adott esetben szubsztituált alkil-, alkenil- vagy alkinilcsoport; Xkarbonil-, tiokarbonil-, szulfonil-, C(X1)2, PO(OR4) vagy =N-R19csoport; X1 hidrogén-, halogénatom, alkil-, -NR4R5, -(alkil)-NR4R5, -C(O)NR4R5, adott esetben szubsztituált alkil-, alkoxi-, halogén-alkoxi-, hdrox-, aril-, aril-alkil-, aril-oxi-, aril-alkoxi-,heteroaril-, heteroaril-alkil-, heterociklil-, heterociklil-alkil-vagy heteroaril-alkoxi-csoport; X2 oxo- vagy tioxocsoport; R1hidrogén-, halogénatom, nitro-, ciano-, halogén-alkil-, alkil-,alkenil-, alkoxi-, halogén-alkoxi-, azido-, stb. csoport. v értéke 0,1, 2, 3 vagy 4; HET adott esetben szubsztituált heteroarilcsoport; R4és R5 hidrogénatom, adott esetben szubsztituált alkil-, aril-, aril-alkil-, heteroaril-, heteroaril-alkil-, heterociklil-, heterociklil-alkil-, vagy R4 és R5 a nitrogénatommal együtt heterociklusoscsoportot képez; Y jelentése azonor R1 jelentésével; R13 és R14hidrogénatom vagy adott esetben szubsztituált alkilcsoport, vagy R13és R14 egyike adott esetben szubsztituált arilcsoport; R15 és R16hidrogénatom, adott esetben szubsztituált alkilcsoport, vagyheterociklil-alkil-csoport; R18 hidrogénatom, adott esetbenszubsztituált alkil-, alkoxi-, halogén-alkoxi-, hidroxi-, aril-alkil-,aril-alkenil-, heteroaril-, heteroaril-alkil-, heteroaril-alkenil-,heterociklil- vagy heterociklil-alkil-csoport; W jelentése kondenzáltgyűrűs csoportokat jelent. és gyógyászatilag elfogadható sóik IL-8avagy IL-8b receptorhoz kötődő kemokin által mediált betegségekkezelésére történő felhasználására alkalmas gyógyszerkészítményekelőállítára vonatkozik. ÓCompounds of the general formula (I) of the invention (I) are shown below - in the formula R -NH-C(X2)-NH-(CR13R14)v-Z group; Z W, HET, optionally substituted alkyl, alkenyl or alkynyl; Xcarbonyl, thiocarbonyl, sulfonyl, C(X1)2, PO(OR4) or =N-R19; X1 is hydrogen, halogen atom, alkyl-, -NR4R5, -(alkyl)-NR4R5, -C(O)NR4R5, optionally substituted alkyl-, alkoxy-, halo-alkoxy-, hydroxy-, aryl-, aryl-alkyl- , aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; X2 is an oxo or thioxo group; R1 is hydrogen, halogen, nitro, cyano, haloalkyl, alkyl, alkenyl, alkoxy, halo- alkoxy, azido, etc. group. v is 0.1, 2, 3 or 4; HET is optionally substituted heteroaryl; R4 and R5 are hydrogen atoms, optionally substituted alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, or R4 and R5 together with the nitrogen atom form a heterocyclic group; Y has the same meaning as R1; R13 and R14 are a hydrogen atom or an optionally substituted alkyl group, or one of R13 and R14 is an optionally substituted aryl group; R15 and R16 are a hydrogen atom, an optionally substituted alkyl group, or a heterocyclylalkyl group; R18 is a hydrogen atom, an optionally substituted alkyl, hydroxy, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heterocyclyl or heterocyclylalkyl group ; W represents fused ring groups. and their pharmaceutically acceptable salts refers to the manufacturer of pharmaceutical preparations suitable for the treatment of diseases mediated by IL-8a or IL-8b receptor-bound chemokines. HE

HU0201582A 1999-06-16 2000-06-15 Use of il-8 receptor antagonist benzimidazoles and benzotriazoles HUP0201582A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14002499P 1999-06-16 1999-06-16
PCT/US2000/016506 WO2000076501A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0201582A2 true HUP0201582A2 (en) 2002-12-28
HUP0201582A3 HUP0201582A3 (en) 2003-02-28

Family

ID=22489379

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201582A HUP0201582A3 (en) 1999-06-16 2000-06-15 Use of il-8 receptor antagonist benzimidazoles and benzotriazoles

Country Status (19)

Country Link
EP (1) EP1185265A4 (en)
JP (1) JP2003501463A (en)
KR (1) KR20020015347A (en)
CN (1) CN1356899A (en)
AR (1) AR024350A1 (en)
AU (1) AU766235B2 (en)
BR (1) BR0011122A (en)
CA (1) CA2377386A1 (en)
CO (1) CO5190696A1 (en)
CZ (1) CZ20014472A3 (en)
HU (1) HUP0201582A3 (en)
IL (1) IL145762A0 (en)
MX (1) MXPA01013005A (en)
NO (1) NO20016052D0 (en)
NZ (1) NZ514696A (en)
PL (1) PL352213A1 (en)
TR (1) TR200103638T2 (en)
WO (1) WO2000076501A1 (en)
ZA (1) ZA200109480B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2321186T3 (en) 2002-10-09 2009-06-03 Schering Corporation TIADIAZOL DIOXIDES AND TIADIAZOL MONOXIDES AS LIGANDOS OF CXC AND CC CHEMIOQUINE RECEPTORS.
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10334309A1 (en) * 2003-07-28 2005-03-03 Aventis Pharma Deutschland Gmbh Substituted thiazole-Benzoisothiazoldioxidderivate, processes for their preparation and their use
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
US7521448B2 (en) 2003-08-21 2009-04-21 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-Kit inhibitors
AU2004268948A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
ATE406356T1 (en) 2003-12-19 2008-09-15 Schering Corp THIADIAZOLES AS CXC AND CC CHEMOKINE RECEPTOR LIGANDS
EP1809619A1 (en) 2004-10-21 2007-07-25 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
US7419995B2 (en) 2004-12-01 2008-09-02 Osi Pharmaceuticals, Inc. N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library
WO2011023081A1 (en) 2009-08-24 2011-03-03 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
CN102060780B (en) * 2010-12-27 2014-11-05 雅本化学股份有限公司 Preparation method of 2-(N-substituted).-aminobenzimidazole derivative
CN111116502A (en) * 2018-10-30 2020-05-08 中国石油化工股份有限公司 One-step method for synthesizing benzotriazole

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
CA2278504A1 (en) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Il-8 receptor antagonists

Also Published As

Publication number Publication date
KR20020015347A (en) 2002-02-27
NO20016052L (en) 2001-12-11
AR024350A1 (en) 2002-10-02
HUP0201582A3 (en) 2003-02-28
ZA200109480B (en) 2002-11-18
TR200103638T2 (en) 2002-04-22
IL145762A0 (en) 2002-07-25
CN1356899A (en) 2002-07-03
CA2377386A1 (en) 2000-12-21
EP1185265A1 (en) 2002-03-13
NO20016052D0 (en) 2001-12-11
CO5190696A1 (en) 2002-08-29
PL352213A1 (en) 2003-08-11
AU766235B2 (en) 2003-10-09
NZ514696A (en) 2004-03-26
CZ20014472A3 (en) 2002-06-12
JP2003501463A (en) 2003-01-14
EP1185265A4 (en) 2004-02-04
MXPA01013005A (en) 2002-07-02
AU5616100A (en) 2001-01-02
BR0011122A (en) 2002-02-26
WO2000076501A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
HUP0201582A2 (en) Use of il-8 receptor antagonist benzimidazoles and benzotriazoles
AU2002304800B2 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
JP6326057B2 (en) Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, methods for their preparation, and their use as kinase inhibitors
MX2007007428A (en) Heterocyclic compounds as ccr2b antagonists.
AR058403A1 (en) PIRIMIDINILOXI AND PIRIDINILOXI SUBSTITUTED UREAS AS INHIBITORS OF PROTEIN KINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY BASAL ACTIVITY.
BRPI0610150A2 (en) compound, prodrug, process for producing the compound, pharmaceutical composition, crf receptor antagonist, and use of crf receptor antagonist
NO20063132L (en) Naphthyridine derivatives and their use as modulators of muscarinic receptors
JP2006522812A5 (en)
NO20092689L (en) Quinuclidinol derivatives as muscarinic receptor antagonists
MY148392A (en) Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
PT1153017E (en) BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS
Verma et al. Heteroaromatic annulation studies on 2-[bis (methylthio) methylene]-1, 3-indanedione: efficient routes to indenofused heterocycles
PE20040828A1 (en) BENZOXAZINONES AS MODULARS OF 5-HYDROXITRIPTAMINE (5-HT)
BRPI0717089A2 (en) QUINOLINONE DERIVATIVES
CA2976121A1 (en) Inhibitors of necroptosis
CA2879816C (en) Methanethione compounds having antiviral activity
PE20091187A1 (en) QUINOLINE-DERIVED COMPOUNDS AS MODULATORS OF THE 5-HT6 SEROTONIN RECEPTOR
WO2016042172A1 (en) Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as s100-inhibitors
MXPA02011464A (en) 1,4 diazepan 2,5 dione derivatives and their use as nk 1 receptor antagonists.
ATE263150T1 (en) IL-8 RECEPTOR ANTAGONISTS
HUP0400854A2 (en) Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists and pharmaceutical compositions containing them
PE20090967A1 (en) DERIVATIVES OF IMIDAZOLIDINE 2,4-DIONA AS MODULATORS OF THE NPY Y2 RECEPTOR
TW200612912A (en) Benzyloxy derivatives as maob inhibitors
Al-Masoudi et al. Synthesis and modeling study of some potential pyrimidine derivatives as HIV inhibitors
Brown et al. The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3 (4H)-yl] benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees